Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus + tacrolimus versus mycophenolate mofetil + tacrolimus in kidney transplant recipients
IRCT20081102001430N3Phase 4Recruiting
- Sponsor
- Behestan Darou
- Start
- Aug 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sirolimus, tacrolimus and mycophenolate mofetil in kidney transplant (2 arms), sponsored by Behestan Darou. Primary endpoint: Kidney transplant rejection. Started Aug 2025; status: recruiting.
02
Drugs
sirolimustacrolimusmycophenolate mofetil
03
Conditions
kidney transplant
Beyond the preview
Go deeper on IRCT20081102001430N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20081102001430N3.